Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07586046 · ClinicalTrials.gov registry record · Phase 2
Defining the Ablative Dose for Y-90 TARE
A Phase 2 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07586046 is a Phase 2 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT07586046, a Phase 2 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.
Interventions
- OTHER Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07586046
The ClinicalTrials.gov registry entry for NCT07586046 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres is the first listed.
NCT07586046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07586046 about?
NCT07586046 is a clinical study titled "Defining the Ablative Dose for Y-90 TARE". This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver t...
What is the current status of trial NCT07586046?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-05. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07586046?
The interventions under investigation include: Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres (OTHER).
Who is sponsoring clinical trial NCT07586046?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.